Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of High Nodal Burden in Patients With Sentinel Node-Positive Luminal ERBB2-Negative Breast Cancer.
Skarping I, Bendahl PO, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Christiansen P, Filtenborg Tvedskov T, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Vrou Offersen B, Olofsson Bagge R, Reimer T, Sund M, Rydén L, de Boniface J. Skarping I, et al. Among authors: kontos m. JAMA Surg. 2024 Dec 1;159(12):1393-1403. doi: 10.1001/jamasurg.2024.3944. JAMA Surg. 2024. PMID: 39320882 Free PMC article. Clinical Trial.
Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study.
Hartmann S, Banys-Paluchowski M, Stickeler E, de Boniface J, Gentilini OD, Kontos M, Seitz S, Kaltenecker G, Wärnberg F, Zetterlund LH, Kolberg HC, Fröhlich S, Kühn T. Hartmann S, et al. Among authors: kontos m. Breast Cancer Res Treat. 2023 Dec;202(3):497-504. doi: 10.1007/s10549-023-07100-0. Epub 2023 Sep 8. Breast Cancer Res Treat. 2023. PMID: 37684426 Free PMC article.
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
de Boniface J, Filtenborg Tvedskov T, Rydén L, Szulkin R, Reimer T, Kühn T, Kontos M, Gentilini OD, Olofsson Bagge R, Sund M, Lundstedt D, Appelgren M, Ahlgren J, Norenstedt S, Celebioglu F, Sackey H, Scheel Andersen I, Hoyer U, Nyman PF, Vikhe Patil E, Wieslander E, Dahl Nissen H, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P; SENOMAC Trialists’ Group; SENOMAC Trialists' Group. de Boniface J, et al. Among authors: kontos m. N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487. N Engl J Med. 2024. PMID: 38598571 Clinical Trial.
Quality assessment of radiotherapy in the prospective randomized SENOMAC trial.
Alkner S, Wieslander E, Lundstedt D, Berg M, Kristensen I, Andersson Y, Bergkvist L, Frisell J, Olofsson Bagge R, Sund M, Christiansen P, Davide Gentilini O, Kontos M, Kühn T, Reimer T, Rydén L, Filtenborg Tvedskov T, Vrou Offersen B, Dahl Nissen H, de Boniface J; SENOMAC Trialists’ Group. Alkner S, et al. Among authors: kontos m. Radiother Oncol. 2024 Aug;197:110372. doi: 10.1016/j.radonc.2024.110372. Epub 2024 Jun 10. Radiother Oncol. 2024. PMID: 38866204 Free article. Clinical Trial.
Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
de Boniface J, Appelgren M, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, Olofsson Bagge R, Reimer T, Sund M, Christiansen P, Rydén L, Filtenborg Tvedskov T; SENOMAC Trialists’ Group. de Boniface J, et al. Among authors: kontos m. Lancet Oncol. 2024 Sep;25(9):1222-1230. doi: 10.1016/S1470-2045(24)00350-4. Epub 2024 Aug 6. Lancet Oncol. 2024. PMID: 39121881 Clinical Trial.
Axillary clearance and chemotherapy rates in ER+HER2- breast cancer: secondary analysis of the SENOMAC trial.
Tvedskov TF, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, Bagge RO, Reimer T, Sund M, Rydén L, Christiansen P, de Boniface J; SENOMAC Trialists' Group. Tvedskov TF, et al. Among authors: kontos m. Lancet Reg Health Eur. 2024 Sep 26;47:101083. doi: 10.1016/j.lanepe.2024.101083. eCollection 2024 Dec. Lancet Reg Health Eur. 2024. PMID: 39386258 Free PMC article.
Anemia Acuity Effect on Transfusion Strategies in Acute Myocardial Infarction: A Secondary Analysis of the MINT Trial.
Carrier FM, Cooper HA, Portela GT, Bertolet M, Lemesle G, Prochaska M, Kim S, Alexander JH, Crozier I, Ducrocq G, Quadros AS, Bagai A, Dracoulakis M, Madan M, Brooks MM, Carson JL, Hébert PC; MINT Investigators. Carrier FM, et al. JAMA Netw Open. 2024 Nov 4;7(11):e2442361. doi: 10.1001/jamanetworkopen.2024.42361. JAMA Netw Open. 2024. PMID: 39485351 Free PMC article. Clinical Trial.
Effect of Four Hemoglobin Transfusion Threshold Strategies in Patients With Acute Myocardial Infarction and Anemia : A Target Trial Emulation Using MINT Trial Data.
Portela GT, Carson JL, Swanson SA, Alexander JH, Hébert PC, Goodman SG, Steg PG, Bertolet M, Strom JB, Fergusson DA, Simon T, White HD, Cooper HA, Abbott JD, Rao SV, Chaitman BR, Fordyce CB, Lopes RD, Daneault B, Brooks MM; MINT Investigators. Portela GT, et al. Ann Intern Med. 2024 Nov;177(11):1489-1498. doi: 10.7326/M24-0571. Epub 2024 Oct 1. Ann Intern Med. 2024. PMID: 39348705 Clinical Trial.
Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Cystic Fibrosis.
Rolsma SL, Sokolow A, Patel PC, Sokolow K, Jimenez-Truque N, Fissell WH, Ryan V, Kirkpatrick CM, Nation RL, Gu K, Teresi M, Fishbane N, Kontos M, An G, Winokur P, Landersdorfer CB, Creech CB. Rolsma SL, et al. Among authors: kontos m. J Infect Dis. 2024 Sep 30:jiae451. doi: 10.1093/infdis/jiae451. Online ahead of print. J Infect Dis. 2024. PMID: 39344185
343 results